1. Home
  2. KYTX
  3. KYTX News

Latest KYVERNA THERAPEUTICS INC (KYTX) News on July 27, 2024

Biotech Stock Roundup: LXRX Up on Regulatory Update, SAVA, LXEO Down on Updates
KYTX

Zacks

8 days ago

Biotech Stock Roundup: LXRX Up on Regulatory Update, SAVA, LXEO Down on Updates

Kyverna wins RMAT designation for stiff-person syndrome for cell therapy candidate
KYTX

Pharmaceutical Technology

10 days ago

Kyverna wins RMAT designation for stiff-person syndrome for cell therapy candidate

Kyverna (KYTX) Gets RMAT Designation for CAR T-Cell Product
KYTX

Zacks

10 days ago

Kyverna (KYTX) Gets RMAT Designation for CAR T-Cell Product

KYTX

MT Newswires

11 days ago

Kyverna Therapeutics Gets FDA RMAT Designation for Stiff-Person Syndrome Treatment; Shares Rise After Hours

Kyverna's KYV-101 Receives U.S. FDA RMAT Designation for KYV-101 in the Treatment of Patients With Refractory Stiff-Person Syndrome
KYTX

PR Newswire

11 days ago

Kyverna's KYV-101 Receives U.S. FDA RMAT Designation for KYV-101 in the Treatment of Patients With Refractory Stiff-Person Syndrome

Kyverna's KYV-101 Receives U.S. FDA IND Clearance for Treatment of Patients With Treatment-Refractory Stiff-Person Syndrome in the KYSA-8 Phase 2 Trial
KYTX

PR Newswire

a month ago

Kyverna's KYV-101 Receives U.S. FDA IND Clearance for Treatment of Patients With Treatment-Refractory Stiff-Person Syndrome in the KYSA-8 Phase 2 Trial

First-in-Disease Use of Kyverna Therapeutics' KYV-101 in Patient With Severe Stiff-Person Syndrome Published in Proceedings of the National Academy of Sciences (PNAS)
KYTX

PR Newswire

a month ago

First-in-Disease Use of Kyverna Therapeutics' KYV-101 in Patient With Severe Stiff-Person Syndrome Published in Proceedings of the National Academy of Sciences (PNAS)

Kyverna Therapeutics and National Institutes of Health Co-Author Seminal Review on Cell Therapy for Autoimmunity in Nature Reviews Immunology
KYTX

PR Newswire

2 months ago

Kyverna Therapeutics and National Institutes of Health Co-Author Seminal Review on Cell Therapy for Autoimmunity in Nature Reviews Immunology

Kyverna Therapeutics to Present Data on 50 Patient Experience at Symposium at EULAR 2024
KYTX

PR Newswire

2 months ago

Kyverna Therapeutics to Present Data on 50 Patient Experience at Symposium at EULAR 2024

Kyverna Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
KYTX

PR Newswire

2 months ago

Kyverna Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results

Kyverna Therapeutics to attend the 2024 American Academy of Neurology (AAN) Annual Meeting in Denver, CO, With Data on KYV-101 in the Treatment of Patients with Neurological Autoimmune Diseases
KYTX

PR Newswire

3 months ago

Kyverna Therapeutics to attend the 2024 American Academy of Neurology (AAN) Annual Meeting in Denver, CO, With Data on KYV-101 in the Treatment of Patients with Neurological Autoimmune Diseases

First-in-Disease Use of Kyverna Therapeutics' KYV-101 in Patients With Progressive Multiple Sclerosis Published in Med
KYTX

PR Newswire

4 months ago

First-in-Disease Use of Kyverna Therapeutics' KYV-101 in Patients With Progressive Multiple Sclerosis Published in Med

Kyverna Therapeutics Provides Business Update and Reports Full Year 2023 Financial Results
KYTX

PR Newswire

4 months ago

Kyverna Therapeutics Provides Business Update and Reports Full Year 2023 Financial Results

Why That Hot Biotech IPO Could Be a Winner
KYTX

The Wall Street Journal

4 months ago

Why That Hot Biotech IPO Could Be a Winner

Kyverna Therapeutics and Stanford University Agree to Evaluate KYV-101 in Patients with Non-Relapsing and Progressive Forms of Multiple Sclerosis
KYTX

PR Newswire

5 months ago

Kyverna Therapeutics and Stanford University Agree to Evaluate KYV-101 in Patients with Non-Relapsing and Progressive Forms of Multiple Sclerosis

How Kyverna is positioned for success on autoimmune therapy: CEO
KYTX

Yahoo Finance Video

5 months ago

How Kyverna is positioned for success on autoimmune therapy: CEO

Kyverna Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
KYTX

PR Newswire

5 months ago

Kyverna Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Kyverna Therapeutics Announces Pricing of Upsized Initial Public Offering
KYTX

PR Newswire

6 months ago

Kyverna Therapeutics Announces Pricing of Upsized Initial Public Offering

Share on Social Networks: